Is MP Stock a Buy, Hold or Sell After Its 31.2% One-Year Decline?

MP Materials’ shares fell 31.2% over the past year, despite Q2 2026 revenue rising 89% year over year to $108.5 million; the company still posted a $32 million operating loss, its 12th consecutive quarterly loss. Start-up costs reached $14 million versus $0.76 million a year earlier, and 2026 capital spending is forecast at $500–$600 million, while 2026 and 2027 earnings estimates have been revised down. Expansion could lift NdPr output and magnet capacity, but execution risks, a 12.52x forward price-to-sales multiple, and a Zacks Strong Sell rating weigh on the near-term outlook.

Analysis

The key issue is earnings quality, not top-line growth: government price-protection income and a mix shift toward processed products can lift reported revenue before proving durable, unsubsidized unit economics. At a premium sales multiple, MP is especially exposed if processing yields, realized prices or magnet margins disappoint. Conversely, if domestic supply security becomes a lasting policy priority, the premium may partly reflect strategic option value rather than near-term earnings.

Over the next 1–3 months, watch whether the production ramp converts into lower cost per unit and whether customer qualification becomes repeat commercial orders. GM testing is not evidence of scaled, contracted demand; similarly, the Apple relationship and drone initiative need quantified volumes to change valuation. The multiple-quarters capacity build creates a second-order risk: rising domestic output could pressure product pricing unless demand grows alongside it. Global supply and pricing—especially from established producers such as Lynas—remain important swing factors.

Over 6–18 months, heavy-rare-earth commissioning and magnet yields could strengthen MP’s strategic position, but concurrent projects compound schedule and capital-allocation risk. A reversal in government support or weaker rare-earth pricing would make that risk more acute. The one-year decline alone is not a valuation catalyst; the market may already discount execution risk, while the premium leaves limited room for further estimate cuts.

Key Decisions for Investors

• Keep MP underweight rather than initiate an unconditional short: the policy and integration optionality can produce sharp upside, but the premium valuation and unproven downstream economics argue against adding ahead of evidence.
• Treat any move toward commercial magnet shipments as a catalyst to verify, not a buy signal. Require disclosed repeat volumes, customer qualification completion and improving realized margins before upgrading; testing deliveries alone do not establish recurring revenue.
• For a relative-value watch, compare MP with Lynas only after checking current valuation, product mix, liquidity and borrow costs. A short-MP/long-Lynas position could express execution-premium compression, but differences in geography and business scope make it an imperfect hedge.
• Falsify the cautious thesis if MP demonstrates sustained unit-cost improvement and positive operating cash generation without relying materially on price-protection income. Reassess downside risk if production or qualification milestones slip, estimates continue falling, or rare-earth prices weaken; verify cash, funding commitments and capex phasing before assessing balance-sheet risk.